White Button Mushroom Extract in Treating Patients With Recurrent Prostate Cancer After Local Therapy

OBJECTIVES:

Primary

- To assess the feasibility and toxicity of prolonged white button mushroom extract
therapy at six different dose levels in patients with biochemically recurrent prostate
cancer after local therapy.

Secondary

- To analyze the effect of this regimen on a variety of biomarkers including testosterone,
dihydrotestosterone, dehydroepiandrosterone, estrogens, aromatase, parameters of immune
function, and circulating tumor cells.

- To assess the effect of this regimen on PSA kinetics as a measure of disease activity in
these patients.

OUTLINE: This is a dose-escalation study.

Patients receive oral white button mushroom extract twice daily on days 1-28. Courses repeat
every 4 weeks in the absence of disease progression or unacceptable toxicity.

Blood and urine samples are collected periodically for pharmacokinetic, pharmacodynamic, and
immunologic correlative studies. Plasma and urine samples are analyzed for quantification of
conjugated unsaturated fatty acids via gas chromatography-mass spectometry. Plasma samples
are analyzed for inhibition of aromatase via aromatase activity analysis and the effect of
treatment on immune cytokines levels via immunobiologic assays. Peripheral blood mononuclear
cells are analyzed for the effect of treatment on immune cell subsets and NK cell function
via multi-parameter flow cytometry; effect of treatment on NK cell activation status via
staining method; and measurement of circulating tumor cells via fluorescence microscopy,
fiber-optic array scanning technology (FAST), or high-speed flow cytometry. Additional serum
samples are collected for future studies.

Patients complete a diary listing days of administration of treatment and side effects.

Inclusion Criteria:

- Patients must have a histologically or cytologically confirmed history of
adenocarcinoma of the prostate Patients must have a PSA failure defined as PSA of >=
0.2 ng/ml that has increased above nadir following prostatectomy If radiation or other
local therapy was used as a primary therapy and no prostatectomy was performed
patients must have PSA increase of 2.0 above post-therapy nadir; PSA value must be
increasing based on two consecutive measurements each separated by at least 2 weeks
with no clinical or radiographic evidence of metastatic disease; PSA values that meet
the criteria for eligibility within 4 weeks of registration are acceptable to document
eligibility for enrollment on this study; PSA level obtained after registration and
prior to the first course will be used as the "baseline" PSA as per the schema but
will not determine eligibility for participation

- Patients must have had at least three PSA measurements over a minimum of three months
available prior to enrollment to this study

- Patients may have received any number of local therapies (radical prostatectomy,
external beam radiation therapy, radioactive seed implantation, cryotherapy)

- Bone scan and computed tomography (CT) scan of the chest, abdomen and pelvis negative
for metastatic disease within 2 months prior to registration

- Patients must have a performance status of 0, 1, or 2

- All patients will have malignancy confirmed by review of their biopsy specimens by the
Division of Pathology, City of Hope National Medical Center; if no pathological
specimen is available for review, the patient may still be included if the patient has
clearly documented prostate cancer per pathology report and a specimen request is
documented as having been made for tissue from the outside facility but a specimen was
unable to be obtained

- Serum creatinine =< 2.5 mg/dL

- Baseline liver function tests including bilirubin =< 1.5 x the institutional upper
limit of normal and serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic
pyruvic transaminase (SGPT) =< 2.5 x the institutional upper limit of normal

- White blood cells (WBC) >= 2000

- Platelets >= 50,000

Exclusion Criteria:

- Patients with evidence of metastatic disease

- PSA progression not verified by sequential rising PSA as discussed in the eligibility
section

- Patients who have received prior cytotoxic chemotherapy or androgen ablative therapy
for recurrent disease

- Patients currently receiving biological response modifiers, or corticosteroids

- Patients are permitted to have received up to 24 months of neoadjuvant or adjuvant
hormone ablation in conjunction with their primary definitive therapy; androgen
deprivation must have been completed at least 6 months prior to registration and
testosterone level must be > 50; no complementary or alternative therapy (e.g. St.
John's Wort, PC-SPES, or other herbal remedies taken for the purpose of treating
prostate cancer) may be given during protocol treatment; patients are allowed to have
received neoadjuvant and/or adjuvant chemotherapy that was completed at least 6 months
prior to registration to the protocol

- Uncontrolled intercurrent illness including, but not limited to, ongoing active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/ social situations that would limit compliance with
study requirements

- Patients with known allergy to mushrooms